Cargando…
A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine
OBJECTIVE: The objective of this study was to implement a model-based approach to identify the optimal allocation of a coronavirus disease 2019 (COVID-19) vaccine in the province of Alberta, Canada. METHODS: We developed an epidemiologic model to evaluate allocation strategies defined by age and ris...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209775/ https://www.ncbi.nlm.nih.gov/pubmed/34138458 http://dx.doi.org/10.1007/s40273-021-01037-2 |
_version_ | 1783709196703760384 |
---|---|
author | Kirwin, Erin Rafferty, Ellen Harback, Kate Round, Jeff McCabe, Christopher |
author_facet | Kirwin, Erin Rafferty, Ellen Harback, Kate Round, Jeff McCabe, Christopher |
author_sort | Kirwin, Erin |
collection | PubMed |
description | OBJECTIVE: The objective of this study was to implement a model-based approach to identify the optimal allocation of a coronavirus disease 2019 (COVID-19) vaccine in the province of Alberta, Canada. METHODS: We developed an epidemiologic model to evaluate allocation strategies defined by age and risk target groups, coverage, effectiveness and cost of vaccine. The model simulated hypothetical immunisation scenarios within a dynamic context, capturing concurrent public health strategies and population behavioural changes. RESULTS: In a scenario with 80% vaccine effectiveness, 40% population coverage and prioritisation of those over the age of 60 years at high risk of poor outcomes, active cases are reduced by 17% and net monetary benefit increased by $263 million dollars, relative to no vaccine. Concurrent implementation of policies such as school closure and senior contact reductions have similar impacts on incremental net monetary benefit ($352 vs $292 million, respectively) when there is no prioritisation given to any age or risk group. When older age groups are given priority, the relative benefit of school closures is much larger ($214 vs $118 million). Results demonstrate that the rank ordering of different prioritisation options varies by prioritisation criteria, vaccine effectiveness and coverage, and concurrently implemented policies. CONCLUSIONS: Our results have three implications: (i) optimal vaccine allocation will depend on the public health policies in place at the time of allocation and the impact of those policies on population behaviour; (ii) outcomes of vaccine allocation policies can be greatly supported with interventions targeting contact reduction in critical sub-populations; and (iii) identification of the optimal strategy depends on which outcomes are prioritised. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40273-021-01037-2. |
format | Online Article Text |
id | pubmed-8209775 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-82097752021-06-17 A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine Kirwin, Erin Rafferty, Ellen Harback, Kate Round, Jeff McCabe, Christopher Pharmacoeconomics Original Research Article OBJECTIVE: The objective of this study was to implement a model-based approach to identify the optimal allocation of a coronavirus disease 2019 (COVID-19) vaccine in the province of Alberta, Canada. METHODS: We developed an epidemiologic model to evaluate allocation strategies defined by age and risk target groups, coverage, effectiveness and cost of vaccine. The model simulated hypothetical immunisation scenarios within a dynamic context, capturing concurrent public health strategies and population behavioural changes. RESULTS: In a scenario with 80% vaccine effectiveness, 40% population coverage and prioritisation of those over the age of 60 years at high risk of poor outcomes, active cases are reduced by 17% and net monetary benefit increased by $263 million dollars, relative to no vaccine. Concurrent implementation of policies such as school closure and senior contact reductions have similar impacts on incremental net monetary benefit ($352 vs $292 million, respectively) when there is no prioritisation given to any age or risk group. When older age groups are given priority, the relative benefit of school closures is much larger ($214 vs $118 million). Results demonstrate that the rank ordering of different prioritisation options varies by prioritisation criteria, vaccine effectiveness and coverage, and concurrently implemented policies. CONCLUSIONS: Our results have three implications: (i) optimal vaccine allocation will depend on the public health policies in place at the time of allocation and the impact of those policies on population behaviour; (ii) outcomes of vaccine allocation policies can be greatly supported with interventions targeting contact reduction in critical sub-populations; and (iii) identification of the optimal strategy depends on which outcomes are prioritised. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40273-021-01037-2. Springer International Publishing 2021-06-17 2021 /pmc/articles/PMC8209775/ /pubmed/34138458 http://dx.doi.org/10.1007/s40273-021-01037-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Article Kirwin, Erin Rafferty, Ellen Harback, Kate Round, Jeff McCabe, Christopher A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine |
title | A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine |
title_full | A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine |
title_fullStr | A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine |
title_full_unstemmed | A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine |
title_short | A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine |
title_sort | net benefit approach for the optimal allocation of a covid-19 vaccine |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209775/ https://www.ncbi.nlm.nih.gov/pubmed/34138458 http://dx.doi.org/10.1007/s40273-021-01037-2 |
work_keys_str_mv | AT kirwinerin anetbenefitapproachfortheoptimalallocationofacovid19vaccine AT raffertyellen anetbenefitapproachfortheoptimalallocationofacovid19vaccine AT harbackkate anetbenefitapproachfortheoptimalallocationofacovid19vaccine AT roundjeff anetbenefitapproachfortheoptimalallocationofacovid19vaccine AT mccabechristopher anetbenefitapproachfortheoptimalallocationofacovid19vaccine AT kirwinerin netbenefitapproachfortheoptimalallocationofacovid19vaccine AT raffertyellen netbenefitapproachfortheoptimalallocationofacovid19vaccine AT harbackkate netbenefitapproachfortheoptimalallocationofacovid19vaccine AT roundjeff netbenefitapproachfortheoptimalallocationofacovid19vaccine AT mccabechristopher netbenefitapproachfortheoptimalallocationofacovid19vaccine |